跳至主要内容
临床试验/NCT01150942
NCT01150942已完成3 期

A Multi-center, Active-control, Randomized, Double-blind Phase 3 Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived Inactivated Japanese Encephalitis Vaccine 'KD-287(JEIMMUGEN INJ.) in Korean Healthy Children Aged 12~23 Months

Boryung Pharmaceutical Co., Ltd1 个研究点 分布在 1 个国家目标入组 205 人开始时间: 2010年8月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
205
试验地点
1
主要终点
immunogenicity

研究概览

简要总结

To assess the immunogenicity and safety of the vero cell-derived inactivated JE vaccine in Korean healthy children aged 12~23 months

详细描述

To compare the Vero cell-derived inactivated Japanese encephalitis(JE) vaccine 'KD-287(JEIMMUGEN INJ.)' with the mouse brain-derived inactivated JE vaccine in terms of the immunogenicity and safety, in Korean healthy children aged 12~23 months

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
12 Months 至 23 Months(Child)
性别
All
接受健康志愿者

入选标准

  • Healthy children aged 12-23 months
  • Written informed consent

排除标准

  • History of documented HIV
  • Known or suspected impairment of immunologic function
  • History of serious chronic disease
  • Received any JE vaccine prior to enrollment

结局指标

主要结局

immunogenicity

时间窗: pre-dose, after 3rd vaccination

the seroconversion rates for JE antibodies 4 weeks after 3rd vaccination

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验